Acquired resistance to immunotherapy characterized by bloody pleural effusion and biomarker exploration: a report of 2 cases | Zendy

Xinyan Zeng | Zendy; Yiruo Zhang | Zendy; Yiyin Zhang | Zendy; Yu Lei | Zendy; Kangsheng Gu | Zendy

Open Access

Acquired resistance to immunotherapy characterized by bloody pleural effusion and biomarker exploration: a report of 2 cases

Author(s) -

Xinyan Zeng,

Yiruo Zhang,

Yiyin Zhang,

Yu Lei,

Kangsheng Gu

Publication year - 2022

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-22-142

Subject(s) - medicine , pleural effusion , bloody , pembrolizumab , bevacizumab , surgery , mesothelioma , oncology , cancer , immunotherapy , pathology , chemotherapy

With the current wide use of checkpoint inhibitors in the treatment of solid tumors, some patients who initially respond to immunotherapy have been shown to develop acquired resistance. However, the manifestation and underlying mechanisms are currently poorly understood. This is the first reported case of acquired resistance and pleural metastasis with uncontrolled massive bloody pleural effusion after immunotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research